Los Angeles, USA, July 15, 2021 (GLOBE NEWSWIRE) -- Aplastic Anemia Pipeline Insight 2021: Emerging Drugs, Key Companies, Clinical Trials Updates
The rise in awareness of Aplastic Anemia has led to the increased Research & Development activities in the pharmaceutical sector and the development of pipeline products such as PF-06462700, REGN7257, Romiplostim, BL-8040, and others.
DelveInsight’s “Aplastic Anemia Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Aplastic Anemia pipeline landscapes. It comprises Aplastic Anemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Aplastic Anemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Aplastic Anemia pipeline products.
Some of the key takeaways from the Aplastic Anemia Pipeline Report
- Major companies such as Kyowa Kirin Co., Ltd., Regeneron Pharmaceuticals, Foresee Pharmaceuticals, Omidubicel, Cellenkos, Hemogenyx, Gamida Cell Ltd., Pfizer, and others are developing potential drug candidates to improve the Aplastic Anemia treatment scenario.
- In June 2019, Kyowa Hakko Kirin received the partial change approval of Romiplate for additional treatment of Aplastic Anemia patients who have had an inadequate response to conventional therapy from Japan's Ministry of Health, Labour, and Welfare (MHLW).
- Hetrombopag, a thrombopoietin receptor agonist being developed by Jiangsu Hengrui Medicine, is registered for aplastic anemia in China to treat Aplastic Anemia.
- Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies. A poster presentation at the American Society of Hematology (ASH) 62nd Annual Meeting in December 2020 showed that patients with severe aplastic anemia treated with omidubicel achieved sustained early engraftment.
- CK 0801 is being developed and investigated in preclinical studies by Cellenkos and the MD Anderson Cancer Center.
- HemoGenyx has been granted FDA orphan drug designation for Hu-PHEC Liver to treat aplastic anemia, enabling a faster route to commercialization to get the therapies and treatments to patients most in need.
Get an overview of pipeline landscape @ Aplastic Anemia Clinical Trials Analysis
Aplastic Anemia is a rare, severe blood disorder due to failure of the bone marrow to produce blood cells. The disease can be moderate, painful, or very severe. Aplastic Anemia treatment is based on the severity. Treatment with immune system-suppressing therapy or a stem cell transplant is required for patients with severe Aplastic Anemia, whereas there is no standard of care for moderate Aplastic Anemia.
Aplastic Anemia Emerging Drugs
- PF-06462700: Pfizer
PF-06462700 is an immunosuppressant/immunosuppressive agent. PF-06462700 is being developed by Pfizer for Aplastic Anemia patients and is currently in the phase III stage of development.
- REGN7257: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is developing REGN7257 for Aplastic Anemia treatment. It is currently in phase I/II stage of development. LB-001 acts as a modulator of Interleukin 2 and immunomodular.
- Romiplostim: Kyowa Kirin Co., Ltd.
Romiplostim, a member of the thrombopoietin (TPO) mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor. Romiplostim is currently being evaluated in Phase II/III clinical trials to treat patients with Aplastic Anemia.
- BL-8040: BioLineRx, Ltd.
BL-8040 (Motixafortide) targets CXCR4, a chemokine receptor and a well-validated therapeutic target that is over-expressed in many human cancers, including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis, therapeutic resistance, and CXCR4 overexpression correlated with poor prognosis. A Phase II clinical trial has been completed for BL-8040 for the treatment of Aplastic Anemia.
For further information, refer to the detailed report @ Aplastic Anemia Pipeline Therapeutics
Scope of Aplastic Anemia Pipeline Drug Insight
- Coverage: Global
- Major Players: 10+ Key Players
- Prominent Players: Kyowa Kirin Co., Ltd., Regeneron Pharmaceuticals, Foresee Pharmaceuticals, Omidubicel, Cellenkos, Hemogenyx, Gamida Cell Ltd., Pfizer, and many others.
- Key Drugs Profiles: 10+Products
- Phases:
· Aplastic Anemia Therapies Late-stage (Phase III)
· Aplastic Anemia Therapies Mid-stage (Phase II)
· Aplastic Anemia Therapies Early-stage (Phase I)
· Aplastic Anemia Pre-clinical stage and Discovery candidates
· Discontinued and Inactive candidates
- Mechanism of Action:
· Thrombopoietin receptor agonists
· Anti-interleukin 2 receptor subunit gamma inhibitors
· Cell replacements
- Molecule Types:
· Vaccines
· Monoclonal Antibody
· Peptides
· Polymer
· Small molecule
- Route of Administration:
· Infusion
· Intradermal
· Intramuscular
· Intranasal
· Oral
· Parenteral
· Subcutaneous
· Topical
- Product Types:
· Monotherapy
· Combination
· Mono/Combination
Key Questions regarding Current Aplastic Anemia Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
- What are the current options for Aplastic Anemia treatment?
- How many companies are developing therapies for the treatment of Aplastic Anemia?
- How many are Aplastic Anemia emerging therapies in the early-stage, mid-stage, and late development stages to treat Aplastic Anemia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Aplastic Anemia market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Aplastic Anemia?
- What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Aplastic Anemia therapies?
- What are the critical designations that have been granted for the emerging therapies for Aplastic Anemia?
- How many patents are granted and pending for the emerging therapies to treat Aplastic Anemia?
Table of Contents
| 1 | Aplastic Anemia Report Introduction |
| 2 | Aplastic Anemia Executive Summary |
| 3 | Aplastic Anemia Overview |
| 4 | Aplastic Anemia – DelveInsight’s Analytical Perspective In-depth Commercial Assessment |
| 5 | Aplastic Anemia Pipeline Therapeutics |
| 6 | Aplastic Anemia Late Stage Products (Registered) |
| 6.1 | Romiplostim: Kyowa Kirin Co., Ltd. |
| 7 | Aplastic Anemia Mid Stage Products (Phase I/II) |
| 7.1 | REGN7257: Regeneron Pharmaceuticals |
| 8 | Aplastic Anemia Therapeutics Assessment |
| 9 | Aplastic Anemia Inactive Products |
| 10 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 11 | Aplastic Anemia Key Companies |
| 12 | Aplastic Anemia Key Products |
| 13 | Aplastic Anemia Unmet Needs |
| 14 | Aplastic Anemia Market Drivers and Barriers |
| 15 | Aplastic Anemia Future Perspectives and Conclusion |
| 16 | Aplastic Anemia Analyst Views |
| 17 | Appendix |
| 18 | About DelveInsight |
Get a customized pipeline report @ Aplastic Anemia Drugs Pipeline Report
Related Reports
DelveInsight's Aplastic Anemia - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Aplastic Anemia - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Aplastic Anemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Aplastic Anemia.
DelveInsight's Anemia In Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast - 2030 report proffers a detailed overview of the disease and understanding of historical and forecasted epidemiology.
DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Chemotherapy Induced Anemia - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
Browse Blog Posts
- Read more here on what is shaping the Alagille Syndrome Market?
- Which companies are vying to get a significant chunk in the Elastomeric Pump Market?
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.